GlaxoSmithKline and the World Health Organization (WHO) announced that they have signed an agreement for the development of a new treatment for malaria called LAPDAP. LAPDAP, a product that combines two existing anti-malarial compounds chlorprogunil and dapsone, is a potential life-saving medicine.